Files
Download Full Text (370 KB)
Contents
- Intratumoral Therapies Offer Novel Cancer Treatment Approach: Injecting cancer treatments such as vaccines and genetically modified bacteria and viruses directly into tumors may shrink or destroy the tumors and stimulate an immune response that attacks tumor cells. These treatments have shown promise in clinical trials, and newer trials are exploring whether such treatments can augment the effectiveness of immunotherapy in patients with metastatic or inoperable disease.
- High-Risk Acute Lymphoblastic Leukemia Subtype Targeted in Upcoming Clinical Trial: Early T cell precursor acute lymphoblastic leukemia (ETP-ALL), an uncommon subtype of T cell acute lymphoblastic leukemia (T-ALL), carries a poor prognosis and low response rate to traditional chemotherapy drugs. But a clinical trial of a targeted agent that shows promise against ETP-ALL will soon be enrolling patients at The University of Texas MD Anderson Cancer Center.
- HOUSE CALL: What Is Metastasis?-Understanding the spread of cancer
- INBRIEF: New Staging System Proposed for HPV-Related Oropharyngeal Cancer
Publication Date
5-1-2016
Publisher
The University of Texas MD Anderson Cancer Center
City
Houston, Texas
Keywords
Subbiah, Vivek; Murthy, Ravi; Coley, William B.; Janku, Filip; Fueyo, Juan; Gomez-Manzano, Candelaria; Lang, Frederick F.; Toniatti, Carlo; Bover, Laura; Ravizzini, Gregory; Khoury, Joseph D.; Jain, Nitin; Sturgis, Erich M.; Neoplasms -- therapy; Clinical Trials as Topic; Cancer Vaccines; Immunotherapy; Clostridium; Oncolytic Viruses; Receptors, OX40; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasm Metastasis; Neoplasm Staging; Human Papillomavirus Viruses; Oropharyngeal Neoplasms.
Disciplines
History of Science, Technology, and Medicine | Oncology
Recommended Citation
Tutt, Bryan and Werner, Katelyn, "OncoLog, Volume 61, Number 05, May 2016" (2016). OncoLog MD Anderson's Report to Physicians (All issues). 269.
https://openworks.mdanderson.org/oncolog/269
Conditions Governing Access
Redacted